DOTmed has learned that ZOLL Medical Corporation has received approval from the U.S. Food and Drug Administration (FDA) to market and sell a new model of the LifeVest(R) wearable defibrillator.

Patients at risk for sudden cardiac arrest benefit from the LifeVest wearable defibrillator, which allows their physicians time to assess their long-term arrhythmic risk and make appropriate plans that could include the decision to implant a cardioverter defibrillator (ICD).

The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. There are over 2,000 patients currently wearing the LifeVest.
The LifeVest is rented to patients like other durable medical equipment (DME), allowing physicians to provide the patient the protection of the LifeVest by placing a medical order directly with ZOLL. From this point, ZOLL manages the process to protect the patient from sudden cardiac arrest from hospital discharge to recovery at home, including fitting the LifeVest to the patient, educating the patient in the hospital prior to release, managing all of medical documentation and insurance paperwork, and addressing via telephone and in person any patient needs once home.

About ZOLL Medical Corporation

ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation and temperature control therapies for the treatment of critical care patients. With products for pacing, defibrillation, circulation, temperature management, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help(R) and See-Thru CPR(R), which help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.

ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. During 2008 ZOLL marked the 25th anniversary of the Company's resuscitation product development. For more information, visit www.zoll.com.

More HCB News